ArticleFrontiers in oncology2025
De-escalation of regional nodal irradiation fields in pT1-2N1 breast cancer patients after breast conserving surgery: retrospective real-world clinical experience.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Regional nodal irradiation (RNI) in pN1 patients with one to three positive axillary lymph node breast cancers remains controversial. This study aimed to evaluate the impact of RNI in patients with pT1-2N1 breast cancer who underwent radiotherapy after breast-conserving surgery (BCS), focusing on risk stratification and defining the extent of RNI as axillary lymph node levels I and II. Methods: Female patients with pT1-2N1 breast cancer after BCS with axillary lymph node dissection or sentinel lymph node biopsy who were treated with radiotherapy between 2009 and 2021 were identified. Radiotherapy included either whole-breast irradiation (WBI) alone or WBI with RNI to axillary levels I and II. Patients were categorized into three risk groups based on pathological T stage, number of positive lymph nodes, and immunohistochemical classification. Results: A total of 464 patients were analyzed, with a median follow-up of 68.5 months. A total of 212 (45.7%) patients received WBI alone, and 252 (54.3%) received WBI with RNI. Overall, RNI did not significantly improve disease-free survival (DFS) (p = 0.317), locoregional recurrence-free survival (LRRFS) (p = 0.321), distant metastasis-free survival (DMFS) (p = 0.452), or overall survival (OS) (p = 0.721). However, RNI demonstrated a significant benefit in terms of LRRFS (p = 0.014) in the high-risk group. Case-control matched analysis showed robust benefits in DFS (p = 0.020), LRRFS (p = 0.030), and marginal improvement in DMFS (p = 0.066) in the high-risk group. The toxicities were comparable between WBI alone and WBI with RNI. Conclusions: RNI omission may be considered in low-risk patients with pT1 and one positive lymph node. High-risk patients with pT2, two to three lymph nodes, or triple-negative breast cancer may benefit from RNI. De-escalation of the RNI extent might be considered for non-inferior survival outcomes with comparable toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.